Menlo Therapeutics Inc (MNLO)

1.35  -0.03 (-2.17%)

After market: 1.38 +0.03 (+2.22%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

Menlo Therapeutics Inc

NASDAQ:MNLO (9/4/2020, 7:18:36 PM)

After market: 1.38 +0.03 (+2.22%)

1.35

-0.03 (-2.17%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorN/A
GICS IndustryN/A
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap226.38M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

MNLO Daily chart

Company Profile

Menlo Therapeutics Inc. is a late stage biopharmaceutical company. It focused on the development of serlopitant and treatment of chronic itch and chronic refractory cough. The company's product pipeline consists of Prurigo Nodularis Itch, Atopic Dermatitis Itch, Psoriasis Itch and Refractory Chronic Cough which are in clinical stage. Menlo Therapeutics Inc. is headquartered in Redwood City, California.

Company Info

Menlo Therapeutics Inc

520 U.S. HIGHWAY 22 SUITE 204

BRIDGEWATER NJ 08807

P: 800-775-7936

CEO: Steven Basta

MNLO News

News Image4 years ago - VYNE Therapeutics Inc.VYNE Therapeutics (formerly Menlo Therapeutics) to Present at the Cantor Fitzgerald and H.C. Wainwright Investment Conferences in September
News Image4 years ago - Seeking AlphaMenlo Therapeutics changes name to Vyne Therapeutics (NASDAQ:MNLO)

Menlo Therapeutics (MNLO) changed its name to Vyne Therapeutics and will trade under the symbol to 'VYNE'; effective trading today."We are excited to launch our new corporate identity as VYNE Therapeutics today, and are honored to be marking this important milestone in our company's history by ringing the Nasdaq closing bell," president & CEO David Domzalski commented.No change in outstanding common shares and stockholders rights.

News Image4 years ago - VYNE Therapeutics Inc.Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE Therapeutics

Will commence trading under new Nasdaq Ticker "VYNE", September 8, 2020

News Image4 years ago - Menlo Therapeutics Inc.Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE Therapeutics
News Image4 years ago - Menlo Therapeutics Inc.Menlo Therapeutics Announces Corporate Name Change to VYNE Therapeutics
News Image4 years ago - Analyst RatingsLifeSci Capital Sticks to Its Buy Rating for Menlo Therapeutics (MNLO)

MNLO Twits

Here you can normally see the latest stock twits on MNLO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example